pSivida to Present at Brean Murray & Company Annual Institutional Inve

    Business Editors

    PERTH, Australia--(BUSINESS WIRE)--Feb. 2, 2005--Global nanotechnology company pSivida Limited (NASDAQ:PSDV; ASX:PSD, Xetra:PSI) announced today that Dr. Roger Aston, Director Strategy, will present at the Brean Murray & Company Annual Institutional Investor Conference on Wednesday, February 2, at 11:15 a.m. US Eastern Time. The conference will be held at the New York Palace Hotel.
    A link to the live web cast and recording of pSivida's presentation will be available on pSivida's website: http://www.psivida.com/News/Presentations.asp.

    pSivida Limited is a global nanotechnology committed to the biomedical sector and the development of products in healthcare. The company's focus is the development and commercialization of a modified form of silicon (porosofied or nano-structured silicon) known as BioSilicon(TM). As a new and exciting biocompatible and biodegradable material, BioSilicon offers multiple potential applications across the high growth healthcare sector, including controlled release drug delivery, targeted cancer therapies (including brachytherapy and localized chemotherapy), tissue engineering and orthopedics. Potential diagnostics applications are being developed through its subsidiary AION Diagnostics Limited.
    More information is available at the company's website: www.psivida.com.

    This document contains forward-looking statements that involve risks and uncertainties. Although the company believes the expectations reflected in such forward-looking statements are reasonable at this time, it can give no assurance that such expectations will prove to be correct. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Actual results could differ materially from those anticipated in these forward-looking statements due to many important factors including: failure to develop applications for BioSilicon due to regulatory, scientific or other issues. Other reasons are contained in cautionary statements in the Registration Statement on Form 20-F filed with the U.S. Securities and Exchange Commission, including, without limitation, under Item 3.D., "Risk Factors" therein. The company does not undertake to update any oral or written forward-looking statements that may be made by or on behalf of pSivida.

--30--NB/ny*

CONTACT: In Australia: pSivida Limited Investor Relations Josh Mann, 61-8-9226-5099 joshuamann@psivida.com or In US: Martin E. Janis & Company, Inc. Beverly Jedynak, 312-943-1100 ext. 12 bjedynak@janispr.com

KEYWORD: NEW YORK AUSTRALIA INTERNATIONAL ASIA PACIFIC INDUSTRY KEYWORD: MEDICAL BIOTECHNOLOGY CONFERENCE CALLS SOURCE: pSivida Limited

Copyright Business Wire 2005